Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin
- PMID: 20169048
- PMCID: PMC2819768
- DOI: 10.2147/opth.s9244
Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin
Abstract
Purpose: To compare the kinetics and speed of kill of Streptococcus pneumoniae and Haemophilus influenzae on exposure to three topical ophthalmic antibiotic solutions.
Materials and methods: Bacterial conjunctivitis isolates of S. pneumoniae and H. influenzae were exposed to 1:1000 dilutions of moxifloxacin 0.5%, tobramycin 0.3%, gentamicin 0.3%, and water (control). At 15, 30, 60, 120, and 180 minutes after exposure, aliquots were collected, cells were cultured, and viable cell counts were determined using standard microbiological methods.
Results: Moxifloxacin achieved 99.9% kill (3-log reduction) at approximately 2 hours for S. pneumoniae and at 15 minutes for H. influenzae. Tobramycin and gentamicin did not achieve 3-log reduction of S. pneumoniae during the 180-minute study period. An increase in bacterial growth was noted for these isolates. Gentamicin took more than 120 minutes to achieve the 3-log reduction of H. influenzae and tobramycin did not reach the 3-log reduction of this pathogen during the 180-minute study period.
Conclusion: Moxifloxacin killed S. pneumoniae and H. influenzae in vitro faster than tobramycin and gentamicin, suggesting its potential clinical benefit as a first-line treatment for bacterial conjunctivitis to minimize patient symptoms and to limit the contagiousness of the disease.
Keywords: Haemophilus influenzae; Streptococcus pneumoniae; aminoglycosides; bacterial conjunctivitis; fluoroquinolones; in vitro; kinetics of kill.
Figures




Similar articles
-
Controlling contagious bacterial conjunctivitis.J Pediatr Ophthalmol Strabismus. 2006 Jan-Feb;43(1):19-26. doi: 10.3928/01913913-20060101-02. J Pediatr Ophthalmol Strabismus. 2006. PMID: 16491721
-
Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies.Adv Ther. 2007 Sep-Oct;24(5):1098-111. doi: 10.1007/BF02877716. Adv Ther. 2007. PMID: 18029337
-
Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.J Antimicrob Chemother. 2010 Jul;65(7):1441-7. doi: 10.1093/jac/dkq127. Epub 2010 Apr 30. J Antimicrob Chemother. 2010. PMID: 20435780 Free PMC article.
-
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.Clin Ther. 2010 Mar;32(3):454-71. doi: 10.1016/j.clinthera.2010.03.013. Clin Ther. 2010. PMID: 20399984 Review.
-
Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.Drugs. 1976;12(3):166-200. doi: 10.2165/00003495-197612030-00002. Drugs. 1976. PMID: 789045 Review.
Cited by
-
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.Drugs. 2011 Jan 1;71(1):89-99. doi: 10.2165/11205840-000000000-00000. Drugs. 2011. PMID: 21175242 Review.
-
The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.Clin Drug Investig. 2011;31(8):543-557. doi: 10.2165/11589020-000000000-00000. Clin Drug Investig. 2011. PMID: 21604820
-
Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops.Microorganisms. 2024 Mar 25;12(4):649. doi: 10.3390/microorganisms12040649. Microorganisms. 2024. PMID: 38674593 Free PMC article. Review.
References
-
- Gigliotti F, Williams WT, Hayden FG, Hendley JO, Benjamin J, Dickens M, et al. Etiology of acute conjunctivitis in children. J Pediatr. 1981;98(4):531–536. - PubMed
-
- Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr. 1993;122(1):10–14. - PubMed
-
- Rose PW, Harnden A, Brueggemann AB, Perera R, Sheikh A, Crook D, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet. 2005;66(9479):37–43. - PubMed
-
- Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2006;43(1):19–26. - PubMed
-
- Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2008;45(6):340–349. - PubMed
LinkOut - more resources
Full Text Sources